Follow the BriaCell Therapeutics Corp. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €29.5m. The latest transaction was reported on 7 July 2026 (46 - Compensation for services). Among the most active insiders: Bondarenko, Jamieson. The full history is openly available.
14
Insider Decl.
n/a
Thresholds
€2m
3 ops.
Buy Volume
n/a
n/a
Sell Volume
23Σ signal
Buys €2mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
22,000 shares@ US$5.3547.9% of flowCommon SharesSEC:0001493152-22-036060:0
Canonical exit: 20 Mar 2023 (T+90)
14 of 14 declarations
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a biopharmaceutical company focused on developing immunotherapeutic treatments for cancer. It specializes in dendritic cell-based therapies to target tumors.